



ANTI-DOPING RULE VIOLATION (ADRVP) MEETING  
 Monday 3<sup>rd</sup> November 9am  
 ASADA Canberra Office- Face to Face meeting

MINUTES

Item no.	Title	Discussion
	Opening	<p>The meeting commenced at 9am.</p> <p>In Attendance:</p> <p>Professor Andrew McLachlan - Chair            Mr Hayden Opie            Dr Diana Robinson            Mr Paul Carey            Mr Stuart Thorn</p> <p>Ms Gina Crossman - Secretariat</p> <p>ASADA Staff in Attendance for presentation of Legal Cases but not during deliberations.            Ms Elen Perdikogiannis – National Manager Legal and Support Services            Ms Emily Fitton - Lawyer</p> <p>Apologies:            Professor Peter Fricker</p>
1.	Disclaimer Conflict of Interest	<ul style="list-style-type: none"> <li>o No conflict of interest was declared by panel members present.</li> </ul>
2.	Presentation of Case Material by ASADA	<ul style="list-style-type: none"> <li>o Explanation of the cases and clarification of any issues were presented by Ms Elen Perdikogiannis and Ms Emily Fitton from the ASADA legal team.</li> <li>o The legal team alerted the panel to the typo error in the notification letters which went to the players on 17<sup>th</sup> October 2014. The solicitors representing the 34 players had been advised of this and their responses to this were indicated to the panel. The two solicitors who represent the players responded by email to indicate that it</li> </ul>



ANTI-DOPING RULE VIOLATION (ADRVP) MEETING  
 Monday 3<sup>rd</sup> November 9am  
 ASADA Canberra Office- Face to Face meeting

MINUTES

Item no.	Title	Discussion
3.	Register of Findings- matters for consideration	<p>was clear what was alleged and there was not an issue with the misstatement and it was assumed to be a typo.</p>
3.	<p>3.1 <u>Brent Prismall</u>            ADRV: Use of a prohibited substance            Substances : Thymosin Beta 4            Date : Between about Jan 2012 and Sept 2012</p> <p>The Panel agreed to place the athlete Brent Prismall on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p>3.2 <u>Stewart Cramer</u>            ADRV: Use of a prohibited substance            Substances : Thymosin Beta 4            Date : Between about Jan 2012 and Sept 2012</p> <p>The Panel agreed to place the athlete Stewart Cramer on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p>3.3 <u>Jobe Watson</u>            ADRV: Use of a prohibited substance            Substances : Thymosin Beta 4            Date : Between about Jan 2012 and Sept 2012</p>	



ANTI-DOPING RULE VIOLATION (ADRVP) MEETING  
Monday 3<sup>rd</sup> November 9am  
ASADA Canberra Office- Face to Face meeting

MINUTES

Item no.	Title	Discussion
		<p>The Panel agreed to place the athlete Jobe Watson on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.4 <u>Ariel Steinberg</u></b> ADRV: Use of a prohibited substance Substances : Thymosin Beta 4 Date : Between about Jan 2012 and Sept 2012</p> <p>The Panel agreed to place the athlete Ariel Steinberg on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.5 <u>Brent Stanton</u></b> ADRV: Use of a prohibited substance Substances : Thymosin Beta 4 Date : Between about Jan 2012 and Sept 2012</p> <p>The Panel agreed to place the athlete Brent Stanton on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.6 <u>Henry Slattery</u></b> ADRV: Use of a prohibited substance</p>



**ANTI-DOPING RULE VIOLATION (ADRVP) MEETING**  
**Monday 3<sup>rd</sup> November 9am**  
**ASADA Canberra Office- Face to Face meeting**

**MINUTES**

Item no.	Title	Discussion
		<p><b>Substances : Thymosin Beta 4</b>  <b>Date : Between about Jan 2012 and Sept 2012</b></p> <p>The Panel agreed to place the athlete Henry Slattery on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.7 <u>Patrick Ryder</u></b>  <b>ADRV: Use of a prohibited substance</b>  <b>Substances : Thymosin Beta 4</b>  <b>Date : Between about Jan 2012 and Sept 2012</b></p> <p>The Panel agreed to place the athlete Patrick Ryder on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.8 <u>Tayte Pears</u></b>  <b>ADRV: Use of a prohibited substance</b>  <b>Substances : Thymosin Beta 4</b>  <b>Date : Between about Jan 2012 and Sept 2012</b></p> <p>The Panel agreed to place the athlete Tayte Pears on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p>



ANTI-DOPING RULE VIOLATION (ADRVP) MEETING  
 Monday 3<sup>rd</sup> November 9am  
 ASADA Canberra Office- Face to Face meeting

MINUTES

Item no.	Title	Discussion
	<p><b>3.9 <u>David Myers</u></b>            ADRV: Use of a prohibited substance            Substances : Thymosin Beta 4            Date : Between about Jan 2012 and Sept 2012</p> <p>The Panel agreed to place the athlete David Myers on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p>	<p><b>3.10 <u>Angus Monfries</u></b>            ADRV: Use of a prohibited substance            Substances : Thymosin Beta 4            Date : Between about Jan 2012 and Sept 2012</p> <p>The Panel agreed to place the athlete Angus Monfries on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p>
	<p><b>3.11 <u>Jake Melsham</u></b>            ADRV: Use of a prohibited substance            Substances : Thymosin Beta 4            Date : Between about Jan 2012 and Sept 2012</p> <p>The Panel agreed to place the athlete Jake Melsham on the Register of Findings for possible non presence anti-doping</p>	



ANTI-DOPING RULE VIOLATION (ADRVP) MEETING  
Monday 3<sup>rd</sup> November 9am  
ASADA Canberra Office- Face to Face meeting

MINUTES

Item no.	Title	Discussion
		<p>rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.12 <u>Mark McVeigh</u></b> ADRVP: Use of a prohibited substance Substances : Thymosin Beta 4 Date : Between about Jan 2012 and Sept 2012</p> <p>The Panel agreed to place the athlete Mark McVeigh on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.13 <u>Nathan Lovett Murray</u></b> ADRVP: Use of a prohibited substance Substances : Thymosin Beta 4 Date : Between about Jan 2012 and Sept 2012</p> <p>The Panel agreed to place the athlete Nathan Lovett Murray on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.14 <u>Samuel Lonergan</u></b> ADRVP: Use of a prohibited substance Substances : Thymosin Beta 4</p>



ANTI-DOPING RULE VIOLATION (ADRVP) MEETING  
 Monday 3<sup>rd</sup> November 9am  
 ASADA Canberra Office- Face to Face meeting

MINUTES

Item no.	Title	Discussion
		<p><b>Date : Between about Jan 2012 and Sept 2012</b></p> <p>The Panel agreed to place the athlete Samuel Loneragan on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.15 <u>Brendan Lee</u></b></p> <p><b>ADRV: Use of a prohibited substance</b></p> <p><b>Substances : Thymosin Beta 4</b></p> <p><b>Date : Between about Jan 2012 and Sept 2012</b></p> <p>The Panel agreed to place the athlete Brendan Lee on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.16 <u>Leroy Jetta</u></b></p> <p><b>ADRV: Use of a prohibited substance</b></p> <p><b>Substances : Thymosin Beta 4</b></p> <p><b>Date : Between about Jan 2012 and Sept 2012</b></p> <p>The Panel agreed to place the athlete Leroy Jetta on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p>



ANTI-DOPING RULE VIOLATION (ADRVP) MEETING  
 Monday 3<sup>rd</sup> November 9am  
 ASADA Canberra Office- Face to Face meeting

MINUTES

Item no.	Title	Discussion
	<p><b>3.17 <u>Michael Hurley</u></b>            ADRV: Use of a prohibited substance            Substances : Thymosin Beta 4            Date : Between about Jan 2012 and Sept 2012</p>	<p>The Panel agreed to place the athlete Michael Hurley on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p>
	<p><b>3.18 <u>Ben Howlett</u></b>            ADRV: Use of a prohibited substance            Substances : Thymosin Beta 4            Date : Between about Jan 2012 and Sept 2012</p>	<p>The Panel agreed to place the athlete Ben Howlett on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p>
	<p><b>3.19 <u>Cale Hooker</u></b>            ADRV: Use of a prohibited substance            Substances : Thymosin Beta 4            Date : Between about Jan 2012 and Sept 2012</p>	<p>The Panel agreed to place the athlete Cale Hooker on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in</p>





ANTI-DOPING RULE VIOLATION (ADRVP) MEETING  
Monday 3<sup>rd</sup> November 9am  
ASADA Canberra Office- Face to Face meeting

MINUTES

Item no.	Title	Discussion
		<p>accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.20 <u>Heath Hocking</u></b> ADRV: Use of a prohibited substance Substances : Thymosin Beta 4 Date : Between about Jan 2012 and Sept 2012 The Panel agreed to place the athlete Heath Hocking on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.21 <u>David Hille</u></b> ADRV: Use of a prohibited substance Substances : Thymosin Beta 4 Date : Between about Jan 2012 and Sept 2012 The Panel agreed to place the athlete David Hille on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.22 <u>Michael Hibberd</u></b> ADRV: Use of a prohibited substance Substances : Thymosin Beta 4</p>



ANTI-DOPING RULE VIOLATION (ADRV) MEETING  
 Monday 3<sup>rd</sup> November 9am  
 ASADA Canberra Office- Face to Face meeting

MINUTES

Item no.	Title	Discussion
		<p><b>Date : Between about Jan 2012 and Sept 2012</b></p> <p>The Panel agreed to place the athlete Michael Hibberd on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.23 <u>Dyson Heppell</u></b></p> <p><b>ADRV: Use of a prohibited substance</b></p> <p><b>Substances : Thymosin Beta 4</b></p> <p><b>Date : Between about Jan 2012 and Sept 2012</b></p> <p>The Panel agreed to place the athlete Dyson Heppell on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.24 <u>Kyle Hardingham</u></b></p> <p><b>ADRV: Use of a prohibited substance</b></p> <p><b>Substances : Thymosin Beta 4</b></p> <p><b>Date : Between about Jan 2012 and Sept 2012</b></p> <p>The Panel agreed to place the athlete Kyle Hardingham on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.25 <u>Scott Gumbleton</u></b></p>



**ANTI-DOPING RULE VIOLATION (ADRVP) MEETING**  
**Monday 3<sup>rd</sup> November 9am**  
**ASADA Canberra Office- Face to Face meeting**

**MINUTES**

Item no.	Title	Discussion
		<p><b>ADRVP: Use of a prohibited substance</b>  <b>Substances : Thymosin Beta 4</b>  <b>Date : Between about Jan 2012 and Sept 2012</b></p> <p>The Panel agreed to place the athlete Scott Gumbleton on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.26 <u>Dustin Fletcher</u></b></p> <p><b>ADRVP: Use of a prohibited substance</b>  <b>Substances : Thymosin Beta 4</b>  <b>Date : Between about Jan 2012 and Sept 2012</b></p> <p>The Panel agreed to place the athlete Dustin Fletcher on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.27 <u>Ricky Dyson</u></b></p> <p><b>ADRVP: Use of a prohibited substance</b>  <b>Substances : Thymosin Beta 4</b>  <b>Date : Between about Jan 2012 and Sept 2012</b></p> <p>The Panel agreed to place the athlete Ricky Dyson on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p>



ANTI-DOPING RULE VIOLATION (ADRVP) MEETING  
Monday 3<sup>rd</sup> November 9am  
ASADA Canberra Office- Face to Face meeting

MINUTES

Item no.	Title	Discussion
		<p><b>3.28 <u>Cory Dell Olio</u></b> ADRV: Use of a prohibited substance Substances : Thymosin Beta 4 Date : Between about Jan 2012 and Sept 2012 The Panel agreed to place the athlete Cory Dell Olio on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.29 <u>Luke Davis</u></b> ADRV: Use of a prohibited substance Substances : Thymosin Beta 4 Date : Between about Jan 2012 and Sept 2012 The Panel agreed to place the athlete Luke Davis on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.30 <u>Alwyn Davey</u></b> ADRV: Use of a prohibited substance Substances : Thymosin Beta 4 Date : Between about Jan 2012 and Sept 2012 The Panel agreed to place the athlete Alwyn Davey on the Register of Findings for possible non presence anti-doping rule</p>



ANTI-DOPING RULE VIOLATION (ADRVP) MEETING  
Monday 3<sup>rd</sup> November 9am  
ASADA Canberra Office- Face to Face meeting

MINUTES

Item no.	Title	Discussion
		<p>violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.1.0 of the NAD Scheme.</p> <p><b>3.3.1 <u>Travis Colyer</u></b> ADRV: Use of a prohibited substance Substances : Thymosin Beta 4 Date : Between about Jan 2012 and Sept 2012</p> <p>The Panel agreed to place the athlete Travis Colyer on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.1.0 of the NAD Scheme.</p> <p><b>3.32 <u>Jake Carlisle</u></b> ADRV: Use of a prohibited substance Substances : Thymosin Beta 4 Date : Between about Jan 2012 and Sept 2012</p> <p>The Panel agreed to place the athlete Jake Carlisle on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.1.0 of the NAD Scheme.</p> <p><b>3.33 <u>Alex Browne</u></b> ADRV: Use of a prohibited substance Substances : Thymosin Beta 4</p>



ANTI-DOPING RULE VIOLATION (ADRVP) MEETING  
 Monday 3<sup>rd</sup> November 9am  
 ASADA Canberra Office- Face to Face meeting

MINUTES

Item no.	Title	Discussion
		<p><b>Date : Between about Jan 2012 and Sept 2012</b></p> <p>The Panel agreed to place the athlete Alex Browne on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>3.34 <u>Thomas Bellchambers</u></b></p> <p><b>ADRV: Use of a prohibited substance</b></p> <p><b>Substances : Thymosin Beta 4</b></p> <p><b>Date : Between about Jan 2012 and Sept 2012</b></p> <p>The Panel agreed to place the athlete Thomas Bell Chambers on the Register of Findings for possible non presence anti-doping rule violation of Use of a Prohibited Substance, namely Thymosin Beta 4. The entry on the Register of Findings to be made in accordance with clause 4.10 of the NAD Scheme.</p> <p><b>Based on the information provided the ADRVP concludes that the athletes have been the victims of deception and the panel consider the athletes to have a low level of culpability in these cases.</b></p>
4.	List of matters in which show cause notices issued.	<ul style="list-style-type: none"> <li>o Not discussed at this meeting.</li> </ul>



**ANTI-DOPING RULE VIOLATION (ADRVP) MEETING**  
Monday 3<sup>rd</sup> November 9am  
ASADA Canberra Office- Face to Face meeting

**MINUTES**

Item no.	Title	Discussion
5.	Other Business	<ul style="list-style-type: none"><li>There was a brief discussion in regard to the method of remuneration of the panel for the extensive preparation for this meeting. Gina to advise the panel of the arrangements for this.</li></ul>
6.	Panel members only discussion	<ul style="list-style-type: none"><li>No discussion.</li></ul>
7.	Next meeting	<ul style="list-style-type: none"><li>Thursday 20<sup>th</sup> November 2014, 2pm</li></ul>

Professor Andrew McLachlan (Chair Anti-Doping Rule Violation Panel)